NICE says Libtayo can be used for advanced cervical cancer
New NICE guidance means that around 90 UK women with cervical cancer should be eligible for treatment with Regeneron's Libtayo each year.
Bispecific antibody firm Ollin raises $330m in bumper round
Ollin has followed its $100m Series A last year with a massive $330m second round that will fund phase 3 trials of its challenger to Roche's Vabysmo.
Astellas' Padcev and Gilead's Trodelvy grab key EU approvals
New approvals in the EU for Astellas' Padcev and Gilead's Trodelvy break new ground in the treatment of bladder and triple-negative breast cancer.
UK's RQ Bio raises $115m for flu prevention drug
RQ Bio has raised $115m for clinical trials of RQB01, a one-shot antibody designed for strain-agnostic protection against seasonal influenza viruses.
EFPIA report adds to pressures on EU drug pricing policy
Pharma trade body EFPIA says access to new medicines is worsening across Europe, as it makes the socioeconomic case for spending more on novel drugs.
Sales & Marketing
Digital
Market Access
Editor's Picks
Editor's Picks
Oncology
Patients
R&D
Partner Content
16th World Clinical Biomarkers & CDx Summit
The globe’s longest-standing, industry-dedicated forum for precision medicine is back.
Inizio Launches Intelligent Congress to Turn Event Investmen...
Inizio, the leading global commercialization partner to the health and life sciences industry, today announced the launch of Intelligent Congress
17th World ADC San Diego | October 12-15, 2026
The World’s Premier Forum to Advance Differentiated ADCs to Redefine Early-Line Oncology Patient Outcomes
6th Rare & Genetic Kidney Disease Drug Development Summit
The 6th Rare & Genetic Kidney Disease Drug Development Summit returns to Boston on August 18–20, 2026, bringing together global leaders advanc
Navigating Change: Key Industry Insights at PHARMAP 2026
PHARMAP returns in 2027 in Berlin, Germany, with Bayer as the Host Sponsor